搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
PharmiWeb
3 天
Recombinant Plasma Protein Therapeutics Market 2032: A Game Changer in Healthcare
The global recombinant plasma protein therapeutics market is a dynamic and rapidly growing sector within the ...
centerforbiosimilars
13 天
BioRationality: A Proposal to Create a New Association With Rational Scientific Agenda
I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...
New Food Magazine
13 天
Alternative proteins: feeding people need not cost the earth
Miranda Knaggs outlines the current state of protein production and discusses the potential of alternative proteins in ...
vegconomist
5 天
All G Secures China’s First Approval for Animal-Free Lactoferrin
Australia's All G (previously All G Foods), which is now focused on precision fermentation-derived milk proteins, announces ...
11 天
on MSN
Self-assembling proteins can be used for higher performance, more sustainable skincare products
If you have a meticulous skincare routine, you know that personal skincare products (PSCPs) are a big business. The PSCP ...
13 天
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical moleculesHCW ...
BioSpace
13 天
SignalChem’s Tau Proteins: Accelerating Neurodegenerative Disease Research
SignalChem Biotech provides diverse recombinant Tau proteins for research, helping advance tau-targeted therapies that may ...
1 天
Fusion Antibodies (LON:FAB) Trading Down 1.2% – What’s Next?
Fusion Antibodies plc (LON:FAB – Get Free Report) shares dropped 1.2% on Friday . The company traded as low as GBX 4.20 ($0.05) and last traded at GBX 4.25 ($0.05). Approximately 116,900 shares were ...
biopharma-reporter
5 天
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular atrophy trial
Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.
13 天
Why Is Penny Stock HCW Biologics Surging On Monday?
HCW Biologics' stock rises as it partners with WY Biotech in an exclusive global license deal, securing $7 milion upfront and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈